International Journal of Molecular Sciences

Journal Browser

► Journal Browser

Special Issue Information

Dear Colleagues,

Haematological malignancies are a broad category of cancers of the hematopoietic system, including leukaemias, lymphomas, multiple myeloma, myeloproliferative neoplasias, and myelodysplastic syndromes. The mechanism by which haematological malignancies such as leukaemia, lymphoma, and myeloma develop and proliferate in vivo is not yet fully understood. Treatment approaches, in addition to allogeneic hematopoietic stem cell transplantation, include single- and bispecific-molecule targeted therapy, such as with CAR-T cells.

This Special Issue focuses on molecular advances in the treatment of haematological malignancies and specifically welcomes original articles and review articles covering critical signalling pathways, host immune responses, pathogenesis, and novel targeted therapies such as chemotherapy, immunotherapy, stem cell transplant, monoclonal antibodies, and CAR-T cells.

Dr. Despina Bazou
Dr. Paul Dowling
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

haematological malignancies
multiple myeloma
biomarkers
tumour microenvironment
genomics
proteomics
extramedullary myeloma
therapy
minimal residual disease
smouldering myeloma

Published Papers (1 paper)

Research

15 pages, 1730 KiB

Open AccessArticle

Chimerism Testing by Next Generation Sequencing for Detection of Engraftment and Early Disease Relapse in Allogeneic Hematopoietic Cell Transplantation and an Overview of NGS Chimerism Studies

by Abdelhamid Liacini, Gaurav Tripathi, Amanda McCollick, Christopher Gravante, Peter Abdelmessieh, Yuliya Shestovska, Leena Mathew and Steven Geier

Int. J. Mol. Sci. 2023, 24(14), 11814; https://doi.org/10.3390/ijms241411814 - 23 Jul 2023

Cited by 1 | Viewed by 1960

Abstract

Chimerism monitoring after allogenic Hematopoietic Cell Transplantation (allo-HCT) is critical to determine how well donor cells have engrafted and to detect relapse for early therapeutic intervention. The aim of this study was to establish and detect mixed chimerism and minimal residual disease using Next Generation Sequencing (NGS) testing for the evaluation of engraftment and the detection of early relapse after allo-HCT. Our secondary aim was to compare the data with the existing laboratory method based on Short Tandem Repeat (STR) analysis. One hundred and seventy-four DNA specimens from 46 individuals were assessed using a commercially available kit for NGS, AlloSeq HCT NGS (CareDx), and the STR-PCR assay. The sensitivity, precision, and quantitative accuracy of the assay were determined using artificially created chimeric constructs. The accuracy and linearity of the assays were evaluated in 46 post-transplant HCT samples consisting of 28 levels of mixed chimerism, which ranged from 0.3–99.7%. There was a 100% correlation between NGS and STR-PCR chimerism methods. In addition, 100% accuracy was attained for the two external proficiency testing surveys (ASHI EMO). The limit of detection or sensitivity of the NGS assay in artificially made chimerism mixtures was 0.3%. We conducted a review of all NGS chimerism studies published online, including ours, and concluded that NGS-based chimerism analysis using the AlloSeq HCT assay is a sensitive and accurate method for donor-recipient chimerism quantification and minimal residual disease relapse detection in patients after allo-HCT compared to STR-PCR assay. Full article

(This article belongs to the Special Issue Molecular Advances in Haematological Malignancies)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Molecular Advances in Haematological Malignancies

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI